Macrophages in human atheroma contain PPARγ: Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro

American Journal of Pathology

Volumn 153, Issue 1, 1998, Pages 17-23

  Marx, Nikolaus ^a   Sukhova, Galina ^a   Murphy, Curran ^a   Libby, Peter ^a   Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ARTICLE; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ENZYME INDUCTION; ENZYME SYNTHESIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; MONONUCLEAR PHAGOCYTE; PATHOGENESIS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

EID: 0031870652     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65540-X     Document Type: Article

References (36)

1. Libby P, Geng Y, Aikawa M, Schoenbeck U, Mach F, Clinton S, Sukhova G, Lee R: Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996, 7:330-335
2. Dollery, C, McEwan, J, Henney, A: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995, 77:863-868
3. Davies M, Richardson P, Woolf N, Katz D, Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cells content. Br Heart J 1993, 69:377-381
4. Lendon CL, Davies MJ, Born GV, Richardson PD: Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991, 87:87-90
5. Nikkari S, O'Brien K, Ferguson M, Hatsukami T, Welgus H, Clowes A: Interstitial collagenase (MMP-1) expression in human carotid atherosclerotics. Circulation 1995, 92:1393-1398
6. Galis Z, Sukhova G, Lark M, Libby P: Increased expression of matrix metalloproteinases and matrix degradation activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503
7. Goetzl E, Banda M, Leppert D: Matrix metalloproteinases in immunity. J Immunol 1996, 156:1-4
8. Welgus H, Campbell E, Cury J, Eisen A, Senior RM, Goldberg G: Neutral metalloproteinases produced by human mononuclear phagocytes: enzyme profile, regulation, and expression during cellular development. J Clin Invest 1990, 86:1496-1502
9. Saren P, Welgus H, Kovanen P: TNF-α and IL-1β selectively induce expression of 92-kd gelatinase by human macrophages. J Immunol 1996, 157:4159-4165
10. Schoenbeck U, Mach F, Sukhova G, Murphy C, Bonnefoy J-Y, Fabunmi R, Libby P: Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes. Circ Res 1997, 81:448-454
11. Schroen DJ, Brinckerhoff C: Nuclear hormone receptors inhibit matrix metalloproteinases (MMP) gene expression through diverse mechanisms. Gene Exp 1996, 6:197-207
12. Schoonjans K., Martin G, Staels B, Auwerx J: Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997, 8:159-166
13. Vidal-Puig AJ, Considine RV, Jimenez-Linan MA, Pories WJ, Caro JF, Flier JS: Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997, 99:2416-2422
14. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR γ2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156
15. Brun R, Tontonoz P, Forman B, Ellis RJ, Evan R, Spiegelman BM: Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 1996, 10:974-984
16. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans R: The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839
17. Forman, BM., Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans R: M. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell 1995, 83:803-812
18. Kliewer SA,. Lenhard JM, Willson TM, Patel I, Morris D, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995, 83:813-819
19. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA: Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995, 270:23975-23983
20. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ. J Biol Chem 1995, 270:12953-12956
21. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996, 39:665-668
22. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 1997, 94:4318-4323
23. Greene M, Blumberg B, McBride O, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer S: Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expression 1995, 4:281-299
24. Jiang C, Ting A, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86
25. Ricote M, Li A, Wilson T, Kelly C, Glass C: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998, 391:79-82
26. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809
27. Raines E, Ross R: Is overamplification of the normal macrophage defensive role critical to lesion development? Ann NY Acad Sci 1997, 811:76-85
28. Galis Z, Sukhova G, Kranzhoefer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995, 92:402-406
29. Henney A, Wakeley P, Davies M, Foster K, Hembry R, Murphy G, Humphries S: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991, 88:8154-8158
30. Galis Z, Sukhova G, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995, 9:974-980
31. 2 and related compounds: an update. Prostaglandins Leukotrienes Essent Fatty Acids 1992, 47:1-12
32. 2. Prostaglandins 1988, 35:277-300
33. Urade Y, Ujihara M, Horigushi Y, Ikai K, Hayaishi O: The major source of endogenous prostaglandin D2 is likely antigen-presenting cells. J Immunol 1989, 143:2982-2989
34. Nolen J, Ludvik B, Beerdsen P: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994, 331:1188-1193
35. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of merformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998, 338:867-872
36. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998, 338:861-866